According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.
Curative Biotechnology Inc. announced a patent cooperation treaty (PCT) application was filed in the U.S. Receiving Office on May 22, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25.
The Application has been accorded international application number PCT/US23/23094.
Earlier this year, the company announced it had successfully completed its investigational new drug (IND) enabling tolerance and toxicology study of Metformin HCL solution by topical instillation (eye drops) in rabbits.
At the time, Paul Michaels, chairman and president of Curative Biotechnology, said the company would move on to preparing its first IND application to move the metformin reformulation into a clinical trial to treat Intermediate dry age-related macular degeneration (AMD) and geographical atrophy (GA) resulting from AMD.”
“Both Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options,” Michaels said at the time. “As previously announced, we will
be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland.”